ERBB2 and breast cancer: Other trials comparing HER2 PT and MT status have evidenced HER2 receptor dynamics [22, 33–36], but the present study is one of the first to demonstrate significantly increased HER2 levels in cerebral entities originating from triple-negative BC PTs [37–40].